Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin

Clinical Cancer Research

Volumn 8, Issue 10, 2002, Pages 3276-3284

  Zellweger, Tobias ^a   Chi, Kim ^a   Miyake, Hideaki ^a   Adomat, Hans ^a   Kiyama, Satoshi ^a   Skov, Kirsten ^a   Gleave, Martin E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CLUSTERIN;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; GENE TECHNOLOGY; HUMAN; HUMAN CELL; NICK END LABELING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIOSENSITIVITY;

ANIMALS; APOPTOSIS; BLOTTING, NORTHERN; CELL DIVISION; CLUSTERIN; COLONY-FORMING UNITS ASSAY; DNA PRIMERS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; MALE; MICE; MICE, NUDE; MOLECULAR CHAPERONES; OLIGONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0036796026     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics 1999. CA - Cancer J. Clin., 49: 8-31, 1999.
2. Hanks, G. E., Hanlon, A. L., Hudes, G., Lee, W. R., Suasin, W., and Schultheiss, T. E. Patterns-of-failure analysis of patients with high pretreatment prostate specific antigen levels treated with radiation therapy: the need for improved systemic and locoregional treatment. J. Clin. Oncol., 14: 1093-1097, 1996.
3. Bolla, M., Gonzalez, D., Warde, P., Dubois, J. B., Mirimanoff, R. O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Gil, T., Collette, L., and Pierat. M. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med., 337: 295-300, 1997.
4. Gleave, M. E., Tolcher, A., Miyake, H., Nelson, C., Brown, B., Beraldi, E., and Goldi, J. Progression to androgen independence is delayed by adjuvant treatment with antisense bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin. Cancer Res., 5: 2891-2898, 1999.
5. Miyake, H., Nelson, C., Rennie, P. S., and Gleave, M. E. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen-independence in prostate cancer. Cancer Res., 60: 170-176, 2000.
6. Reed, J. C. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol. Oncol. Clin. N. Am., 9: 451-473, 1995.
7. Kyprianou, N., King, E. D., Bradbury, D., and Rhee, J. G. Bcl-2 overexpression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int. J. Cancer, 70: 341-348, 1997.
8. Miyake, H., Nelson, C., Rennie, P. S., and Gleave, M. E. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene. testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res., 60: 2547-2554, 2000.
9. Scherr, D. S., Vaughan, E. D., Wei, J., Chung, M., Felsen, D., Allbright, R., and Knudsen, B. S. Bcl-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J. Urol., 162: 12-16, 1999.
10. Montpetit, M. L., Lawless, K. R., and Tenniswood, M. Androgen-repressed messages in the rat ventral prostate. Prostate, 8: 25-36, 1986.
11. Sensibar, J. A., Sutkowski, D. M., Raffo, A., Buttyan, R., Griswold, M. D., Sylvester, S. R., Kozlowski, J. M., and Lee, C. Prevention of cell death induced by tumor necrosis factor α in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res., 55: 2431-2437, 1995.
12. Connor, J., Buttyan, R., Olsson, C. A., D'Agati, V., O'Toole, K., and Sawczuk, I. S. SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis. Kidney Int., 39: 1098-1103, 1991.
13. May, P. C., Lampert-Etchells, M., Johnson, S. A., Poirier, J., Masters, J. N., and Finch, C. E. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron, 5: 831-839, 1990.
14. Kyprianou, N., English, H. F., Davidson, N. E., and Isaacs, J. T. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res., 51: 162-166, 1991.
15. Wunsche, W., Tenniswood, M. P., Schneider, M. R., and Vollmer, G. Estrogenic regulation of clusterin mRNA in normal and malignant endometrial tissue. Int. J. Cancer, 76: 684-688, 1998.
16. Humphreys, D. T., Carver, J. A., Easterbrook-Smith, S. B., and Wilson, M. R. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J. Biol. Chem., 274: 6875-6881, 1999.
17. Miyake, H., Chi, K. N., and Gleave, M. E. Antisense testosterone-repressed prostate message-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin. Cancer Res., 6: 1655-1663, 2000.
18. Tamm, I., Dorken, B., and Hartmann, G. Antisense therapy in oncology: new hope for an old idea? Lancet, 358: 489-497, 2001.
19. July, L. V., Akbari, M., Zellweger, T., Jones; E. C., Goldenberg, S. L., and Gleave, M. E. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate, 50: 179-188, 2002.
20. Zellweger, T., Miyake, H., Monia, B., Cooper, S., and Gleave, M. Efficacy of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-o-(2-methoxy) ethyl chemistry. J. Pharmacol. Exp. Ther., 298: 934-940, 2001.
21. Zellweger, T., Miyake, H., July, L., Akbari, M., Kiyama, S., and Gleave, M. E. Chemosensitization of a human renal cell cancer model by antisense TRPM-2 oligodeoxynucleotides both in vitro and in vivo. Neoplasia, 3: 360-367, 2001.
22. Miyake, H., Hara, I., Kamidono, S., and Gleave, M. E. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin. Cancer Res., 7: 4245-4252, 2001.
23. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol., 119: 493-501, 1992.
24. Zelefsky, M. J., Leibel, S. A., Gaudin, P. B., Kutcher, G. J., Fleshner. N. E., and Venkatramen, E. S. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 41: 491-500, 1998.
25. Leibel, S. A., Hanks, G. E., and Kramer, S. Patterns of care outcome studies: results of the national practice in adenocarcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys., 10: 401-409, 1984.
26. Movsas, B., Chapman, J. D., Horwitz, E. M., Pinover, W. H., Greenberg, R. E., Hanlon, A. L., Iyer, R., and Hanks, G. E. Hypoxic regions exist in human prostate carcinoma. Urology, 53: 11-18, 1999.
27. Crooke, S. T. Therapeutic applications of oligonucleotides. Annu. Rev. Pharmacol. Toxicol., 32: 329-376, 1992.
28. Monia, B. P., Johnston, J. F., Geiger, T., Muller, M., and Fabbro, D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against c-raf kinase. Nat. Med., 2: 668-675, 1996.
29. Cucco, C., and Calabretta, B. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxy-nucleotides. Cancer Res., 56: 4332-4337. 1996.
30. Ziegler, A., Luedke, G. H., Fabbro, D., Altman, K. H., Stahel, R. A., and Zangemeister-Wittke, U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the bcl-2 coding sequence. J. Natl. Cancer Inst. (Bethesda), 89: 1027-1036, 1997.
31. Miyake, H., Tolcher, A., and Gleave, M. E. Antisense bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res., 59: 4030-4034, 1999.
32. Geiger, T., Muller, M., Monia, B. P., and Fabbro, D. Antitumor activity of a c-raf antisense oligodeoxynucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. Clin. Cancer Res., 3: 1179-1185, 1997.
33. Jansen, B., Schlagbauer-Wadl, H., Brown, B. D., Bryan, R. N., van Elisas, A., Muller, M., Wolff, K., Eichler, H. G., and Pehamberger, H. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med., 4: 232-234, 1998.
34. Campbell, M. J., Dawson, M., and Koeffler, H. P. Growth inhibition of DU-145 prostate cancer cells by a bcl-2 antisense oligodeoxynucleotide is enhanced by N-(2-hydroxyphenyl) all-trans retinamide. Br. J. Cancer, 77: 739-744, 1998.
35. Miyake, H., Tolcher, A., and Gleave, M. E. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense bcl-2 oligodeoxynucleotides. J. Natl. Cancer Inst. (Bethesda), 92: 34-41, 2000.
36. Ohnishi, T., Taki, T., Hiraga, S., Arita, N., and Morita, T. In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochem. Biophys. Res. Commun., 245: 319-324, 1998.
37. Turner, B. C., Haffty, B. G., Narayanan, L., Yuan, J., Havre, P. A., Gumbs, A. A., Kaplan, L., Burgaud, J. L., Carter, D., Baserga, R., and Glazer, P. M. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res., 57: 3079-3083, 1997.
38. Soldatenkov, V. A., Dritschilo, A., Wang, F. H., Olah, Z., Anderson, W. B., and Kasid, U. Inhibition of raf-1 protein kinase by antisense phosphorothioate oligodeoxynucleotide is associated with sensitization of human laryngeal squamous carcinoma cells to gamma radiation. Cancer J. Sci. Am., 3: 13-20, 1997.
39. Kyprianou, N., and Rock, S. Radiation-induced apoptosis of human prostate cancer cells is independent of mutant p53 overexpression. Anticancer Res., 18: 897-905, 1998.
40. Yang, C. R., Leskov, K., Hosley-Eberlein, K., Criswell, T., Pink, J. J., Kinsella, T. J., and Boothman, D. A. Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death. Proc. Natl. Acad. Sci. USA, 97: 5907-5912, 2000.
41. Kang, S. W., Lim, S. W., Choi, S. H., Chun, B. G., Park, I. S., and Min, B. H. Antisense oligonucleotide of clusterin mRNA induces apoptotic cell death and prevents adhesion of rat ASC-17D Sertoli cells. Mol. Cells, 10: 193-198, 2000.
42. Boise, L. H., Gonzalez-Garcia, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nunez, G., and Thompson, C. B. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell, 74: 597-608, 1993.
43. Rouayrenc, J. F., Boise, L. H., Thompson, C. B., Privat, A., and Patey, G. Presence of the long and the short forms of bcl-x in several human and murine tissues. C. R. Acad. Sci. III, 318: 537-540, 1995.
44. Minn, A. J., Boise, L. H., and Thompson, C. B. Bcl-x(S) antagonizes the protective effects of bcl-x(L). J. Biol. Chem., 271: 6306-6312, 1996.
45. Wong, P., Pineault, J., Lakins, J., Taillefer, D., Leger, J., Wang, C., and Tenniswood, M. Genomic organization and expression of the rat TRPM-2 (clusterin) gene, a gene implicated in apoptosis. J. Biol. Chem., 268: 5021-5031, 1993.
46. Lakins, J., Bennett, S. A., Chen, J. H., Arnold, J. M., Morrissey, C., Wong, P., O'Sullivan, J., and Tenniswood, M. Clusterin biogenesis is altered during apoptosis in the regressing rat ventral prostate. J. Biol. Chem., 273: 27887-27895, 1998.